Julie Grant

Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas.

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Raised $289,500,000.00 from The Column Group.

Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation.

Raised $110,999,994.00 from Arkin Holdings, Mission BioCapital, F-Prime Capital, OUP (Osage University Partners), Canaan Partners, Monograph Capital and Mass General Brigham Ventures.

Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.

Raised $687,500,000.00 from Fairmount Funds Management, Braidwell, Deerfield, Wellington Management, Access Biotechnology and Frazier Healthcare Partners.

Glooko as a digital health company that offers a diabetes management platform to help users monitor and control their blood glucose levels.

Raised $301,000,000.00 from Health Catalyst Capital, Canaan Partners and Georgian.

CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies.

Raised $345,423,000.00 from Wellington Management, Cormorant Asset Management, Deerfield, Casdin Capital, Tekla Capital Management, Perceptive Advisors, Venrock and Redmile Group.